midodrine has been researched along with rifamycins in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanafy, AS; Hassaneen, AM | 1 |
| Aronsohn, A; Dong, T; Gautham Reddy, K; Te, HS | 1 |
1 trial(s) available for midodrine and rifamycins
| Article | Year |
|---|---|
Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Topics: Aldosterone; Anti-Infective Agents; Ascites; Blood Pressure; Body Weight; Diuretics; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Midodrine; Paracentesis; Renin; Rifamycins; Rifaximin; Single-Blind Method; Treatment Outcome; Vasoconstrictor Agents | 2016 |
1 other study(ies) available for midodrine and rifamycins
| Article | Year |
|---|---|
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Case-Control Studies; End Stage Liver Disease; Female; Gastrointestinal Microbiome; Hepatorenal Syndrome; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Midodrine; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Rifamycins; Rifaximin; Severity of Illness Index; Vasoconstrictor Agents | 2016 |